Clinical Trial Update: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating AC682 for locally advanced or metastatic estrogen receptor-positive breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• AC682

Snippet

Sponsor: Accutar Biotechnology Inc | Conditions: Breast Cancer | Phase 1 | Status: TERMINATED